Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7831769 | 1.00 | RXFP1 (0.37) | RXFP1CSF1ROPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7831785 | 1.00 | RXFP1 (0.37) | RXFP1CSF1ROPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15929815 | 0.90 | HTR3A (0.36) | RXFP1OPRK1ALDH1A1KMT2AMEN1 | |
| Vosaroxin SCHEMBL15933161 | 0.90 | HTR3A (0.35) | RXFP1CSF1RALDH1A1KMT2AMEN1 | |
| Vosaroxin SCHEMBL3207291 | 0.90 | HTR3A (0.35) | RXFP1CSF1RALDH1A1KMT2AMEN1 | |
| Vosaroxin SCHEMBL195037 | 0.90 | HTR3A (0.35) | RXFP1CSF1RALDH1A1KMT2AMEN1 | |
| Vosaroxin SCHEMBL674441 | 0.90 | HTR3A (0.35) | RXFP1CSF1RALDH1A1KMT2AMEN1 | |
| SCHEMBL7832312 | 0.89 | OPRK1 (0.34) | RXFP1CSF1ROPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7832308 | 0.89 | OPRK1 (0.34) | RXFP1CSF1ROPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7832305 | 0.89 | OPRK1 (0.34) | RXFP1CSF1ROPRK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676774-B2 | Compounds and compositions for treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | claimed |
| US-20170101404-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | claimed |
| US-20190084978-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-9969730-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9839630-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170226104-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2382214-B1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9676774-B2 | Compounds and compositions for treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676774-B2 | Compounds and compositions for treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170101404-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170101404-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-8124773-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2354138-A1 | Compounds and compositions for treatment of cancer | Sunesis Pharmaceuticals, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS, INC. | 2011-04-14 | — | — | US | disclosed |
| WO-2011028979-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| EP-0787726-B1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-5817669-A | A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0787726-A1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | CYP7A1, MT-ND1, DNM1 | RXFP1 3918/4885CSF1R 4248/4885OPRK1 269/4885 |
| US-20170101404-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | RXFP1 4592/4885CSF1R 4017/4885OPRK1 940/4885 |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | RXFP1 4375/4885CSF1R 2669/4885OPRK1 79/4885 |
| US-20170226104-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | RXFP1 4375/4885CSF1R 2669/4885OPRK1 79/4885 |
| US-20190084978-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | RXFP1 4375/4885CSF1R 2669/4885OPRK1 79/4885 |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | RXFP1 4592/4885CSF1R 4017/4885OPRK1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.